★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Becton, Dickinson and Company (BDX) Moat Analysis
Becton, Dickinson and Company
BDX · New York Stock Exchange
Partial score covering 71% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
BD now reports Medical Essentials, Connected Care, BioPharma Systems and Interventional after the February 2026 separation of Biosciences and Diagnostic Solutions. Fiscal Q2 2026 continuing revenue was $4.714B. The strongest moats are in Connected Care, where infusion and medication-management systems integrate with hospital records and pull through dedicated disposables and services, and BioPharma Systems, where drug-delivery components are qualified into regulated drug products. Medical Essentials benefits from manufacturing productivity, but standalone needles, tubes and syringes are recurring products rather than an installed-base moat and face tender pressure. Generic authorization and quality-system requirements are shared across qualified suppliers, so compliance claims are removed. Interventional's procedure-driven disposables and implants generate repeat demand but the cited evidence does not show an installed-base tie or another structural barrier, leaving that segment without a separately evidenced moat. Recalls, Alaris remediation, tariffs, China volume-based procurement and hospital capital cycles remain key risks.
Primary segment
Medical Essentials
Market structure
Competitive
Market share
—
HHI: —
Coverage
4 segments · 5 tags
Updated 2026-07-12
Segments
Medical Essentials
Single-use medical consumables and specimen collection systems
Revenue
35.2%
Structure
Competitive
Pricing
weak
Share
—
Peers
Connected Care
Hospital medication management, infusion systems, and patient monitoring platforms
Revenue
24.5%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
BioPharma Systems
Prefillable drug delivery and pharmaceutical packaging components for injectable drugs
Revenue
11.1%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Interventional
Interventional and surgical medical devices (vascular, urology, critical care, and surgery)
Revenue
29.2%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Medical Essentials
Single-use medical consumables and specimen collection systems
Revenue_share uses BD six months ended 2026-03-31 continuing segment revenue: Medical Essentials $3.242B of $9.200B total. Operating_profit_share uses segment income: Medical Essentials $1.142B of $3.345B total segment income.
Operational Excellence
Supply
Operational Excellence
Strength
Durability
Confidence
Evidence
Scale manufacturing + productivity programs reduce unit costs and support supply reliability for high-volume consumables.
Operational Excellence moat: definition, examples, and stocks
Erosion risks
- Tariffs and higher labor costs offset productivity gains
- Prolonged disruptions in sterilization or critical component supply
- Manufacturing footprint complexity increases execution risk
Leading indicators
- Segment gross margin and COGS % of revenue
- On-time delivery and inventory turns
- CAPEX for automation and capacity expansion
Counterarguments
- Competitors can replicate lean programs over time; advantage may narrow
- Regional/low-cost producers can undercut prices in tender markets
Connected Care
Hospital medication management, infusion systems, and patient monitoring platforms
Revenue_share uses BD six months ended 2026-03-31 continuing segment revenue: Connected Care $2.252B of $9.200B total. Operating_profit_share uses segment income: Connected Care $699M of $3.345B total segment income.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Infusion, dispensing/automation and monitoring systems embed into hospital IT/clinical workflows (EMR integration), raising switching and retraining costs.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Regulatory actions (warning letters, consent decree) restricting sales or requiring costly remediation
- Cybersecurity incidents affecting connected devices
- Open interoperability standards lowering switching costs
Leading indicators
- Installed base growth and remediation progress for infusion platforms
- Software/service revenue mix and renewal rates
- Backlog/remaining performance obligations for installations
Counterarguments
- Hospitals can switch platforms over multi-year replacement cycles if clinical or economic benefits justify it
- Interoperability standards and middleware can reduce platform lock-in
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Devices (infusion, dispensing, monitoring) drive recurring sales of dedicated disposables, accessories and service/maintenance.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Competitors displace hardware placements, reducing future pull-through
- Pricing pressure on disposables as hospitals seek standardization
- Supply disruptions reduce utilization and customer satisfaction
Leading indicators
- Infusion/disposal utilization rates and attach rates
- Service contract renewal rates
- Disposable revenue per installed device
Counterarguments
- Disposable ecosystems can be replicated; customers may demand open, cross-compatible sets
- Pricing on consumables is often negotiated aggressively by large health systems
Long Term Contracts
Demand
Long Term Contracts
Strength
Durability
Confidence
Evidence
Multi-year service contracts and pending installations create contracted revenue and increase customer inertia.
Long Term Contracts moat: definition, examples, and stocks
Erosion risks
- Customer delays/cancellations of capital installations
- Renegotiation risk if performance issues occur
- Transition to subscription models may compress margins
Leading indicators
- Backlog conversion and installation pace
- Deferred revenue and service contract liabilities
- Customer satisfaction/NPS for installed platforms
Counterarguments
- Contracts can be renegotiated at renewal; customers may use competitive bids to reset pricing
- Operational issues (recalls, downtime) can override contractual inertia
BioPharma Systems
Prefillable drug delivery and pharmaceutical packaging components for injectable drugs
Revenue_share uses BD six months ended 2026-03-31 continuing segment revenue: BioPharma Systems $1.019B of $9.200B total. Operating_profit_share uses segment income: BioPharma Systems $365M of $3.345B total segment income.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Prefillable syringes and self-injection systems are qualified into customer drug products; switching typically requires re-testing, regulatory updates and supply re-validation.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Large pharma customers may dual-source or switch for new drug programs
- Quality issues in primary packaging can cause rapid customer loss and liability
- Shift toward alternative delivery formats reduces demand for certain prefillable categories
Leading indicators
- Share of biologics-oriented prefillable solutions
- Capacity expansion and defect/scrap rates
- Major pharma customer wins/losses and contract renewals
Counterarguments
- Customers can qualify multiple suppliers at launch to reduce dependency
- Competitors with similar quality and capacity can match offerings in mature product categories
Interventional
Interventional and surgical medical devices (vascular, urology, critical care, and surgery)
Revenue_share uses BD six months ended 2026-03-31 continuing segment revenue: Interventional $2.687B of $9.200B total. Operating_profit_share uses segment income: Interventional $1.139B of $3.345B total segment income.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
MD&A attributes Medical segment gross margin improvement to continuous improvement, supply-chain optimization and other productivity initiatives.
Direct support for operational excellence as a cost/scale advantage.
10-K notes the updated BD Alaris infusion system includes interoperability features that connect with electronic medical record systems.
Direct evidence of integration with EMR workflows, a driver of lock-in.
10-K lists Medication Management Solutions product lines including infusion systems, automated dispensing, supply management and enterprise informatics/analytics.
Shows BD sells workflow software/automation, not just hardware, increasing switching costs.
10-K states BD's U.S. infusion pump organizational unit operates under an FDA consent decree related to Alaris infusion pumps.
Important counterweight to the moat: regulatory constraints can erode trust and sales momentum.
10-K describes infusion therapy delivery systems that include infusion pumps and dedicated disposables/IV-related products.
Evidence of consumable pull-through tied to installed devices.
Showing 5 of 8 sources.
Risks & Indicators
Erosion risks
- Tariffs and higher labor costs offset productivity gains
- Prolonged disruptions in sterilization or critical component supply
- Manufacturing footprint complexity increases execution risk
- Regulatory actions (warning letters, consent decree) restricting sales or requiring costly remediation
- Cybersecurity incidents affecting connected devices
- Open interoperability standards lowering switching costs
Leading indicators
- Segment gross margin and COGS % of revenue
- On-time delivery and inventory turns
- CAPEX for automation and capacity expansion
- Installed base growth and remediation progress for infusion platforms
- Software/service revenue mix and renewal rates
- Backlog/remaining performance obligations for installations
Research BDX elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.